TrialThe British journal of dermatology2021

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.

K A Papp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.